Literature DB >> 19303620

Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.

Pavel Pugach1, Neelanjana Ray, Per Johan Klasse, Thomas J Ketas, Elizabeth Michael, Robert W Doms, Benhur Lee, John P Moore.   

Abstract

HIV-1 variants resistant to small molecule CCR5 inhibitors such as vicriviroc (VVC) have modified Env complexes that can use both the inhibitor-bound and -free forms of the CCR5 co-receptor to enter target cells. However, entry via the inhibitor-CCR5 complex is inefficient in some, but not all, cell types, particularly cell lines engineered to express CCR5. We investigated the effect of increasing CCR5 expression, and hence the density of the inhibitor-CCR5 complex when a saturating inhibitor (VVC) concentration was present, by using 293-Affinofile cells, in which CCR5 expression is up-regulated by the transcriptional activator, ponasterone. When CCR5 expression was low, the resistant virus entered the target cells to a lesser extent when VVC was present than absent. However, at a higher CCR5 level, there was much less entry inhibition at a constant, saturating VVC concentration. We conclude that the relative decrease in entry of a VVC-resistant virus in some cell types results from its less efficient use of the VVC-CCR5 complex, and that increasing the CCR5 expression level can compensate for this inefficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303620      PMCID: PMC2674391          DOI: 10.1016/j.virol.2009.02.044

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  37 in total

1.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

Authors:  Masanori Baba; Hiroshi Miyake; Xin Wang; Mika Okamoto; Katsunori Takashima
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Interaction of small molecule inhibitors of HIV-1 entry with CCR5.

Authors:  Christoph Seibert; Weiwen Ying; Svetlana Gavrilov; Fotini Tsamis; Shawn E Kuhmann; Anandan Palani; Jayaram R Tagat; John W Clader; Stuart W McCombie; Bahige M Baroudy; Steven O Smith; Tatjana Dragic; John P Moore; Thomas P Sakmar
Journal:  Virology       Date:  2006-02-21       Impact factor: 3.616

4.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

Authors:  Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding
Journal:  Top HIV Med       Date:  2006 Aug-Sep

5.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

6.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:  Per Johan Klasse
Journal:  Virology       Date:  2007-09-07       Impact factor: 3.616

8.  Genetic acceleration of AIDS progression by a promoter variant of CCR5.

Authors:  M P Martin; M Dean; M W Smith; C Winkler; B Gerrard; N L Michael; B Lee; R W Doms; J Margolick; S Buchbinder; J J Goedert; T R O'Brien; M W Hilgartner; D Vlahov; S J O'Brien; M Carrington
Journal:  Science       Date:  1998-12-04       Impact factor: 47.728

9.  Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

Authors:  Fotini Tsamis; Svetlana Gavrilov; Francis Kajumo; Christoph Seibert; Shawn Kuhmann; Tom Ketas; Alexandra Trkola; Anadan Palani; John W Clader; Jayaram R Tagat; Stuart McCombie; Bahige Baroudy; John P Moore; Thomas P Sakmar; Tatjana Dragic
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

10.  Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry.

Authors:  Rachid Sougrat; Alberto Bartesaghi; Jeffrey D Lifson; Adam E Bennett; Julian W Bess; Daniel J Zabransky; Sriram Subramaniam
Journal:  PLoS Pathog       Date:  2007-05-04       Impact factor: 6.823

View more
  25 in total

1.  HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Authors:  Jennifer M Pfaff; Craig B Wilen; Jessamina E Harrison; James F Demarest; Benhur Lee; Robert W Doms; John C Tilton
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

Review 2.  Coreceptors and HIV-1 pathogenesis.

Authors:  Paul R Gorry; Petronela Ancuta
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

3.  Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Authors:  Zahra F Parker; Shilpa S Iyer; Craig B Wilen; Nicholas F Parrish; Kelechi C Chikere; Fang-Hua Lee; Chuka A Didigu; Reem Berro; Per Johan Klasse; Benhur Lee; John P Moore; George M Shaw; Beatrice H Hahn; Robert W Doms
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

4.  HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Authors:  Annette N Ratcliff; Wuxian Shi; Eric J Arts
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

5.  HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.

Authors:  Michael Roche; Martin R Jakobsen; Jasminka Sterjovski; Anne Ellett; Filippo Posta; Benhur Lee; Becky Jubb; Mike Westby; Sharon R Lewin; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

6.  HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Authors:  John C Tilton; Heather Amrine-Madsen; John L Miamidian; Kathryn M Kitrinos; Jennifer Pfaff; James F Demarest; Neelanjana Ray; Jerry L Jeffrey; Celia C Labranche; Robert W Doms
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

7.  Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.

Authors:  Richard D Sloan; Daniel A Donahue; Björn D Kuhl; Tamara Bar-Magen; Mark A Wainberg
Journal:  Retrovirology       Date:  2010-05-13       Impact factor: 4.602

8.  A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.

Authors:  Samantha H Johnston; Michael A Lobritz; Sandra Nguyen; Kara Lassen; Shirley Delair; Filippo Posta; Yvonne J Bryson; Eric J Arts; Tom Chou; Benhur Lee
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

9.  Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.

Authors:  Caroline Agrawal-Gamse; Fang-Hua Lee; Beth Haggarty; Andrea P O Jordan; Yanjie Yi; Benhur Lee; Ronald G Collman; James A Hoxie; Robert W Doms; Meg M Laakso
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

Review 10.  Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.

Authors:  Kelechi Chikere; Tom Chou; Paul R Gorry; Benhur Lee
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.